Carvedilol

Carvedilol
Clinical data
Trade names	Coreg, others
Other names	BM-14190; BM14190
AHFS/Drugs.com	Monograph
MedlinePlus	a697042
License data	US DailyMed: Carvedilol;
Routes of; administration	By mouth
Drug class	Non-selective beta blocker; Alpha-1 blocker
ATC code	C07AG02 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	25–35%
Protein binding	98%
Metabolism	Liver (CYP2D6, CYP2C9)
Elimination half-life	7–10 hours
Excretion	Urine (16%), feces (60%)
Identifiers
	IUPAC name (±)-[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine;
CAS Number	72956-09-3 ;
PubChem CID	2585;
IUPHAR/BPS	551;
DrugBank	DB01136 ;
ChemSpider	2487 ;
UNII	0K47UL67F2;
KEGG	D00255 ;
ChEBI	CHEBI:3441 ;
ChEMBL	ChEMBL723 ;
PDB ligand	CVD (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID8022747 ;
ECHA InfoCard	100.117.236
Chemical and physical data
Formula	C24H26N2O4
Molar mass	406.482 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES COc1ccccc1OCCNCC(O)COc3cccc4[nH]c2ccccc2c34;
	InChI InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3 ; Key:OGHNVEJMJSYVRP-UHFFFAOYSA-N ;
	(verify)

Carvedilol, sold under the brand name Coreg among others, is a beta blocker medication, that may be prescribed for the treatment of high blood pressure (hypertension) and chronic heart failure with reduced ejection fraction (also known as HFrEF or systolic heart failure). Beta-blockers as a collective medication class are not recommended as routine first-line treatment of high blood pressure for all patients, due to evidence demonstrating less effective cardiovascular protection and a less favourable safety profile when compared to other classes of blood pressure-lowering medications.

Common side effects include dizziness, tiredness, slowed heart rate, low blood pressure, nausea, and shortness of breath. Severe side effects may include bronchospasm. Safety during pregnancy or breastfeeding is unclear. Use is not recommended in those with liver problems. Carvedilol is a nonselective beta blocker and alpha-1 blocker. How it improves outcomes is not entirely clear but may involve dilation of blood vessels.

Carvedilol was patented in 1978 and approved for medical use in the United States in 1995. Carvedilol is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 35th most commonly prescribed medication in the United States, with more than 16 million prescriptions.